Local view for "http://purl.org/linkedpolitics/eu/plenary/2001-03-15-Speech-4-030"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20010315.4.4-030"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
". – Mr President, we live in exciting times. In our own lifetimes there have been massive and amazing advances in science and technology. New industries have appeared, become commonplace, and have provided a better quality of life, higher standards of living, new and better jobs and better working conditions.
For Europe to keep its position in the economic forefront globally and to provide the standards we have come to expect, it has been essential for us to grasp these new technologies. Biotechnology is yet another of these industries. We ignore or side-step it at our peril. Like all new technologies, there are bound to be concerns: environmental, ethical and safety concerns. They must be fully and very openly discussed and studied with the public; they must be monitored and safeguarded by effective regulation.
Issues such as privacy and confidentiality in an era of genetic predictions require further study and perhaps specific legislation. We signal this need in the report and take no predetermined position. This is for later, after proper debate. I would suggest that Amendments Nos 9 and 27 are premature in that they seek to close off such consideration and decision. It is incumbent on us to encourage our scientists, entrepreneurs and business managers to take full advantage of the potential of biotechnology and bring this potential to the people of Europe and to the world, especially the less well-provided developing world.
Biotechnology – the life and plant sciences which it encompasses – offers major advances in medicines and health care, to prevent and cure diseases and disabilities which for so long have blighted the lives of so many men, women and children in our constituencies and world-wide. Biotechnology offers major advances in the production of food in Europe to the advantage of farmers and consumers alike and benefits those parts of the world which struggle against drought and saline soils and fast-increasing populations. It offers crops that eliminate vitamin A deficiency and blindness for millions. It will use fewer pesticides and herbicides and therefore improve the environment and natural habitats.
With valuable opinions from the Committee on Agriculture and Rural and Development and the Committee on the Environment, Public Health and Consumer Policy, for which I sincerely thank their draftsmen, the Committee on Industry, External Trade, Research and Energy has considered all the implications and decisively calls for us in Parliament, the Commission, the Council and the Member State governments to give this industry the support and commitment which it deserves and so badly needs.
Following several years of reticence and indecision, we are well behind our main competitors in the USA. American R[amp]D expenditure on biotechnology is three-and-a-half times that of Europe, employment is over three times and biotech revenues four times.
It is not only the USA: Brazil, Canada, China, India, Israel, Japan, Thailand, Singapore are all embracing biotechnology and actively promoting their indigenous industries. There is no time to lose if Europe is to take its proper place. We have the scientists, the research establishments and the scientific capability. We have the basis of a successful industry, with entrepreneurs, investors and business managers. But, for too long, these have been discouraged by negative and sceptical attitudes in government and political circles, public opinion and the media, by unsympathetic fiscal regimes, by a risk-averse culture and cumbersome legal structures.
The Lisbon Council promised to make Europe the most competitive and dynamic knowledge-based economy in the world. Now we look to the Stockholm Council to fulfil that promise on biotechnology, which is precisely one of the most important means for reaching that much-quoted target. We look to the Commission to rouse itself, to shed its reticence and give a resolute lead with a bio-Europe action plan. We look to the Member States to get on with the job of implementing the outstanding directives and providing the positive environment for their biotech industries to develop and prosper. Our scientists and entrepreneurs are watching intently. What happens here today, in Stockholm this month, in Brussels and the Member States in the next few months, will decide whether they emigrate elsewhere or seek their futures here in Europe.
I ask my colleagues in Parliament to give this report their full support. I ask the Commission to respond to it with vigour, determination and singleness of purpose."@en1
|
| lpv:spokenAs | |
| lpv:unclassifiedMetadata |
Named graphs describing this resource:
The resource appears as object in 2 triples